Source briefing
Clinical Characterization of Invasive Meningococcal Disease Epidemic, Uzbekistan, 2026
B. B. Rakhimov et al.
Read →
Source briefing
ICH E14/S7B (R1) Q&As: The clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs – Questions and Answers
ICH E14/S7B (R1) Q&As: The clinical evaluation of QT/ QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs - Questions and Answers
Read →Source briefing
Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 23, Status: Authorised
Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 23, Status: Authorised
Read →Source briefing
Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study
by Tianfang Shao, Mariana R. Neves, Molly Franke, Carole Mitnick, Jennifer Furin, Ted Cohen, Reza Yaesoubi Background Fluoroquinolones (FQs) are a cornerstone of most all-oral, shorter regimens endorsed by the World Health Organization for the treatment of rifampicin-resistant…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 5, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn
Read →Source briefing
Jyothi Tirumalasetty on Asthma Inhalers and Climate Change
Jyothi Tirumalasetty, MD, a Stanford Medicine allergist, immunologist, and researcher, joins The Future of Medicine to explain an overlooked source of health care emissions: the propellants used in many common asthma inhalers.In this episode, Dr. Tirumalasetty explains how…
Read →Source briefing
The longitudinal care cascade for hypertension in people with and without HIV in South Africa: A clinic-based observational study
by Siphamandla Bonga Gumede, Jennifer Manne-Goehler, Elizabeth Kelechi Oladimeji, Nicola Bulled, Alana T. Brennan, Samanta Tresha Lalla-Edward Background Hypertension (HTN) constitutes a major and growing public health challenge in South Africa, a setting where HIV prevalence also remains…
Read →